8-K: Ensysce Stockholders Approve Key Proposals, Elect Directors

Ensysce Biosciences, Inc. stockholders approved the full issuance of shares and warrants, increased the share pool for its incentive plan, and re-elected two Class I Directors at its annual meeting.

Summary

• The annual meeting of stockholders of Ensysce Biosciences, Inc. was held on January 7, 2026.
• Stockholders approved the full issuance of common stock and exercise of warrants to an investor, for purposes of complying with Nasdaq Listing Rule 5635(d), with 541,882 votes For, 195,475 Against, and 1,970 Abstentions.
• The amendment of the 2021 Omnibus Incentive Plan was approved, increasing the aggregate number of shares of common stock that may be issued under the plan from 121,457 shares to 721,457 shares, with 439,446 votes For, 297,044 Against, and 2,837 Abstentions.
• William Chang and Lee Rauch were elected as Class I Directors, with terms expiring at the 2028 annual meeting, receiving 518,597 and 516,907 votes For, respectively.
• Baker Tilly US, LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025, with 1,659,662 votes For, 105,399 Against, and 4,806 Abstentions.
• A fifth proposal, which would have given discretion to adjourn the meeting to solicit additional proxies, was not submitted to a vote.

Sentiment

Score: 7

Explanation: The filing indicates successful passage of all key management-backed proposals, which is generally positive for corporate stability and operational flexibility. However, the notable 'Against' votes and high 'Broker Non-Votes' suggest some level of shareholder disengagement or dissent on certain matters, slightly tempering the overall positive sentiment.

Positives

• Stockholders approved the issuance of shares and warrants, ensuring compliance with Nasdaq Listing Rule 5635(d).
• The increase in the Omnibus Incentive Plan share pool from 121,457 to 721,457 shares provides greater flexibility for future equity compensation, aiding in talent attraction and retention.
• The re-election of Class I Directors, William Chang and Lee Rauch, indicates continued confidence in the current board leadership.
• The ratification of Baker Tilly US, LLP as the independent registered public accounting firm ensures continuity in financial oversight for the fiscal year ending December 31, 2025.

Negatives

• A significant number of votes (195,475) were cast against the share and warrant issuance, and 297,044 against the incentive plan increase, indicating some level of shareholder dissent or concern.
• Substantial Broker Non-Votes (1,030,540) were recorded for the first three proposals, suggesting a portion of shares were not voted on these discretionary matters.

Future Outlook

NA

Management Comments

• Dr. Lynn Kirkpatrick, President and Chief Executive Officer, signed the report on behalf of Ensysce Biosciences, Inc.

Industry Context

This filing reflects standard corporate governance practices for a publicly traded biotech company, ensuring compliance with exchange rules and maintaining an incentive plan for talent. The approval of share issuance and incentive plan increases are common for growth-oriented companies in the biotech sector to fund operations and attract key personnel.

Comparison to Industry Standards

• The approval of an equity incentive plan increase is a common practice among biotech companies to attract and retain key talent, aligning with industry standards for compensation structures.
• The re-election of directors and ratification of auditors are routine corporate governance actions, consistent with practices across publicly traded companies.
• The need for shareholder approval for share issuance under Nasdaq Listing Rule 5635(d) is a standard compliance requirement for companies listed on Nasdaq, similar to peers.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Approval of share issuance and warrants could lead to dilution but ensures compliance. The incentive plan increase could also lead to future dilution but is intended to align management/employee interests. Re-election of directors provides board stability.
• Employees/Management: The increased share pool for the Omnibus Incentive Plan provides more equity compensation opportunities, potentially boosting morale and retention.
• Investors: The successful passage of proposals provides clarity on corporate governance and compliance, which can be viewed positively.

Next Steps

• The newly elected Class I Directors, William Chang and Lee Rauch, will serve until the 2028 annual meeting.
• Baker Tilly US, LLP will continue as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

Key Dates

Recommendation

The filing details routine corporate governance matters and the successful passage of proposals, including an increase in the equity incentive plan and director re-elections. While these are generally positive for operational stability and talent retention, they do not present new material information that would fundamentally alter the company's valuation or strategic direction. The notable 'Against' votes and high 'Broker Non-Votes' on some proposals suggest some level of shareholder caution, but not enough to warrant a 'sell' or 'strong sell.' Therefore, a 'hold' recommendation is appropriate as these results confirm ongoing corporate operations without providing a strong catalyst for significant upward or downward movement.

Keywords

Ensysce Biosciences, ENSC, Stockholder Meeting, Annual Meeting, Nasdaq Listing Rule 5635(d), Common Stock, Warrants, Omnibus Incentive Plan, Director Election, Corporate Governance, Baker Tilly US LLP, Independent Auditor